10x Genomics stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 68 to 76.
Can You Really Time The Stock Market?
This proprietary rating tracks market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the last 52 weeks compares to other publicly traded companies.
Over 100 years of market history reveals that the market's biggest winners typically have an RS Rating of above 80 as they begin their largest runs. See if 10x Genomics stock can continue to rebound and clear that threshold.
Is 10x Genomics Stock A Buy?
10x Genomics stock recently reclaimed its 200-day moving average. Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock manages to form a base and break out.
The life science technology company reported 0% EPS growth last quarter, while sales growth came in at 10%. The next quarterly results are expected on or around Aug. 7.
10x Genomics stock holds the No. 42 rank among its peers in the Medical-Products industry group. ResMed, Boston Scientific and Insulet are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
